| 1 |
Wang H, Zhu L, Feng X, Zhang H, Luo Q, Chen F. Oridonin induces G2/M cell cycle arrest and apoptosis in human oral squamous cell carcinoma. European Journal of Pharmacology 2017;815:282-9. [DOI: 10.1016/j.ejphar.2017.09.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 2 |
Wang C, Yang D, Jiang L, Wang S, Wang J, Zhou K, Shi X, Chang L, Liu Y, Ke Y, Liu H. Jesridonin in combination with paclitaxel demonstrates synergistic anti-tumor activity in human esophageal carcinoma cells. Bioorganic & Medicinal Chemistry Letters 2017;27:2058-62. [DOI: 10.1016/j.bmcl.2017.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 3 |
Yang H, Khan AR, Liu M, Fu M, Ji J, Chi L, Zhai G. Stimuli-responsive polymeric micelles for the delivery of paclitaxel. Journal of Drug Delivery Science and Technology 2020;56:101523. [DOI: 10.1016/j.jddst.2020.101523] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 4 |
Shuang W, Hou L, Zhu Y, Li Q, Hu W. Mcl-1 stabilization confers resistance to taxol in human gastric cancer. Oncotarget 2017;8:82981-90. [PMID: 29137317 DOI: 10.18632/oncotarget.20222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Ren X, Zhao B, Chang H, Xiao M, Wu Y, Liu Y. Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signaling pathway in canine mammary gland tumor cells. Mol Med Rep. 2018;17:8289-8299. [PMID: 29658576 DOI: 10.3892/mmr.2018.8868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Riestra-Ayora J, Sánchez-Rodríguez C, Palao-Suay R, Yanes-Díaz J, Martín-Hita A, Aguilar MR, Sanz-Fernández R. Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma: in vivo murine model. Drug Deliv 2021;28:1376-88. [PMID: 34180747 DOI: 10.1080/10717544.2021.1923863] [Reference Citation Analysis]
|
| 7 |
Guo S, Zhang Y, Wu Z, Zhang L, He D, Li X, Wang Z. Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin. Biomed Pharmacother 2019;118:109225. [PMID: 31325705 DOI: 10.1016/j.biopha.2019.109225] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 8 |
Wang M, Chen L, Huang W, Jin M, Wang Q, Gao Z, Jin Z. Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes. Int J Nanomedicine 2019;14:1385-400. [PMID: 30863067 DOI: 10.2147/IJN.S195375] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
